This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Leszek, J. Articles by Gamian, A. Search for Related Content PubMed PubMed Citation Articles by Leszek, J. Articles by Gamian, A. Social Bookmarking                         What's this?

Analysis of Serum of Patients With Alzheimer’s Disease for the Level of Advanced Glycation End Products

Department of Psychiatry, Medical University, Wrocaw, Poland, jleszek{at}psych.am.wroc.pl

Krzysztof Mayszczak, MD

Department of Psychiatry, Medical University, Wrocaw, Poland

Adam Barty, MSc

Institute of Immunology and Experimental Therapy, Wrocaw, Poland

Magda Staniszewska, PhD

Institute of Immunology and Experimental Therapy, Wrocaw, Poland

Andrzej Gamian, PhD

Institute of Immunology and Experimental Therapy, Wrocaw, Poland

Data on the serum level of advanced glycation end products (AGEs) in Alzheimer’s disease (AD) patients are scarce, although a specific biochemical marker easy to detect in body fluids is desired for an early diagnosis of disease and to monitor the effects of therapeutic treatment. In the current study, the content of AGEs was examined with an immunochemical assay in the sera of AD patients, in the frame of a search for a biochemical marker of disease. Subjects with AD and vascular dementia (VaD) were included in the study (n = 30; age range, 68-70 years). The results were compared to the healthy control groups. The enzyme-linked immunosorbent assay (ELISA) inhibition test for the determination of AGEs is based on a rabbit anti-AGE, affinity-purified antibody and a model AGE-myoglobin antigen, in which a serum sample treated with proteinase K is used as an inhibitor. For the measurement of immune complexes and anti-AGE antibodies, the corresponding ELISA tests have been applied. The AGE level in the VaD group (49.5 U_AGE) was higher than in AD patients (46.1 U_AGE). The level of total AGEs in the sera of AD patients was significantly lower than in the control group (50/51.6 U_AGE). These relations were not observed with regard to the immune complexes and anti-AGE antibody levels in AD (70.2 U_IC/0.027 U_IgG) and VaD (83 U_IC/0.034 U_IgG) patients because the levels of these parameters were similar to the controls (76.2 U_IC/0.042 U_IgG). The work revealed the lower level of circulating serum AGEs in patients with AD in relation to healthy controls.

Key Words: Alzheimer’s disease • vascular dementia • glycation products • advanced glycation end products • AGEs • biological markers

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 21, No. 5, 360-365 (2006)
DOI: 10.1177/1533317506291075


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?